○○学科

Atsuko Takagi

  (高木 敦子)

Profile Information

Affiliation
University Research Administrator, Osaka Sangyo University
Degree
Doctor of Engineering(Jul, 1985)
大阪大学工学修士(Mar, 1981, 大阪大学)
奈良女子大学理学士(Mar, 1979, 奈良女子大学)

J-GLOBAL ID
200901049532549229
researchmap Member ID
0000010994

Papers

 50
  • Ming Li, Ken-Ichi Hirano, Yoshihiko Ikeda, Masahiro Higashi, Chikako Hashimoto, Bo Zhang, Junji Kozawa, Koichiro Sugimura, Hideyuki Miyauchi, Akira Suzuki, Yasuhiro Hara, Atsuko Takagi, Yasuyuki Ikeda, Kazuhiro Kobayashi, Yoshiaki Futsukaichi, Nobuhiro Zaima, Satoshi Yamaguchi, Rojeet Shrestha, Hiroshi Nakamura, Katsuhiro Kawaguchi, Eiryu Sai, Shu-Ping Hui, Yusuke Nakano, Akinori Sawamura, Tohru Inaba, Yasuhiko Sakata, Yoko Yasui, Yasuyuki Nagasawa, Shintaro Kinugawa, Kazunori Shimada, Sohsuke Yamada, Hiroyuki Hao, Daisaku Nakatani, Tomomi Ide, Tetsuya Amano, Hiroaki Naito, Hironori Nagasaka, Kunihisa Kobayashi
    Orphanet journal of rare diseases, 14(1) 134-134, Jun 11, 2019  Peer-reviewed
    Triglyceride deposit cardiomyovasculopathy (TGCV) is a phenotype primarily reported in patients carrying genetic mutations in PNPLA2 encoding adipose triglyceride lipase (ATGL) which releases long chain fatty acid (LCFA) as a major energy source by the intracellular TG hydrolysis. These patients suffered from intractable heart failure requiring cardiac transplantation. Moreover, we identified TGCV patients without PNPLA2 mutations based on pathological and clinical studies. We provided the diagnostic criteria, in which TGCV with and without PNPLA2 mutations were designated as primary TGCV (P-TGCV) and idiopathic TGCV (I-TGCV), respectively. We hereby report clinical profiles of TGCV patients. Between 2014 and 2018, 7 P-TGCV and 18 I-TGCV Japanese patients have been registered in the International Registry. Patients with I-TGCV, of which etiologies and causes are not known yet, suffered from adult-onset severe heart disease, including heart failure and coronary artery disease, associated with a marked reduction in ATGL activity and myocardial washout rate of LCFA tracer, as similar to those with P-TGCV. The present first registry-based study showed that TGCV is an intractable, at least at the moment, and heterogeneous cardiovascular disorder.
  • Ken-ichi Hirano, Masahiro Higashi, Hideyuki Miyauchi, Atsuko Takagi, Yasuyuki Ikeda, Yusuke Nakano, Tetsuya Amano, for, the Japan TGCV, Study Group
    Annals of Nuclear Cardiology, accepted(1) 47-49, 2019  Peer-reviewed
  • Atsuko Takagi, Yasuyuki Ikeda, Kunihisa Kobayashi, Kazuhiro Kobayashi, Yoshihiko Ikeda, Junji Kozawa, Hideyuki Miyauchi, Ming Li, Chikako Hashimoto, Yasuhiro Hara, Satoshi Yamaguchi, Akira Suzuki, Tatsushi Toda, Hironori Nagasaka, Ken-ichi Hirano
    Biochemical and Biophysical Research Communications, 495(1) 646-651, Jan 1, 2018  Peer-reviewedLead author
    Triglyceride deposit cardiomyovasculopathy (TGCV) is a rare and newly identified disease among patients requiring cardiac transplantation. TGCV is characterized by cardiomyocyte steatosis and triglyceride (TG)-deposit atherosclerosis, resulting from the abnormal intracellular metabolism of TG. TGCV is classified into primary and idiopathic types. Primary TGCV carries ultra-rare genetic mutations in the adipose triglyceride lipase (ATGL), a rate-liming enzyme that hydrolyzes intracellular TG in adipose and non-adipose tissues. Idiopathic TGCV, first identified among autopsied individuals with diabetes mellitus (DM) with severe heart diseases, shows no ATGL mutations and its causes and underlying mechanisms are still unknown. TGCV is difficult to diagnose in daily clinics, thereby demanding feasible diagnostic procedures. We aimed to develop an assay to measure ATGL activity using peripheral leucocytes. Human his6-ATGL was expressed in COS1 cells, purified to homogeneity, and used to raise a polyclonal antibody neutralizing TG-hydrolyzing activity of ATGL. We developed a selective immunoinactivation assay (SIIA) for the quantitation of ATGL activity in cell lysates of leucocytes by the antibody neutralizing ATGL activities. ATGL activity was measured in 13 idiopathic TGCV patients, with two patients with primary TGCV as the negative control. Healthy (non-DM) and DM controls without heart diseases were also subjected. The developed SIIA assay revealed significant reduction in ATGL activity in leucocytes from patients with idiopathic TGCV who did not carry ATGL mutations as compared with non-DM and DM controls. Thus, ATGL in leucocytes may be an important biomarker for the diagnosis of TGCV and our assay may provide insights into pathophysiology and elucidate the underlying mechanism of TGCV and related disorders.
  • Akira Suzuki, Satoshi Yamaguchi, Ming Li, Yasuhiro Hara, Hideyuki Miyauchi, Yoshihiko Ikeda, Bo Zhang, Masahiro Higashi, Yasuyuki Ikeda, Atsuko Takagi, Hironori Nagasaka, Kunihisa Kobayashi, Yasuhiro Magata, Toshiaki AoyamaI, Ken-ichi Hirano
    J Oleo Science, 67(8) 983-989, 2018  Peer-reviewed
  • Sawa Minohara, Sung Kwan Bae, Saori Sugiyama, Noriko Shibata, Toshifumi Gushima, Junichi Motoshita, Shinji Shimoda, Atsuko Takagi, Yasuyuki Ikeda, Kazuhiro Takahashi
    Clinical Case Reports, 6(9) 1-5, 2018  Peer-reviewed
    We report a case of non-alcoholic steatohepatitis complicated with acute pancreatitis induced by hypertriglyceridemia in a young Japanese woman. A precise examination of the lipid profile showed decreased lipoprotein lipase (LPL) and hepatic triglyceride lipase activity levels, while the LPL mass was at the minimum level of the normal range.

Misc.

 103

Books and Other Publications

 13

Presentations

 199

Research Projects

 1

Other

 1